Home > Publications Database > Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. > print

001     276323
005     20250209000740.0
024 7 _ |a 10.1038/s41467-025-56293-z
|2 doi
024 7 _ |a pmid:39881147
|2 pmid
024 7 _ |a altmetric:173615359
|2 altmetric
037 _ _ |a DZNE-2025-00286
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Bolsewig, Katharina
|0 0000-0003-3116-7789
|b 0
245 _ _ |a Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738752241_16407
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Dopa Decarboxylase
|0 EC 4.1.1.-
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Dopamine Agents
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Lewy Body Disease: drug therapy
|2 MeSH
650 _ 2 |a Lewy Body Disease: blood
|2 MeSH
650 _ 2 |a Lewy Body Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Dopa Decarboxylase: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Parkinson Disease: drug therapy
|2 MeSH
650 _ 2 |a Parkinson Disease: blood
|2 MeSH
650 _ 2 |a Parkinson Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Dopamine Agents: therapeutic use
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
700 1 _ |a Willemse, Eline A J
|b 1
700 1 _ |a Sánchez-Juan, Pascual
|b 2
700 1 _ |a Rábano, Alberto
|0 0000-0001-9320-6566
|b 3
700 1 _ |a Martínez, Minerva
|0 0000-0002-9036-2595
|b 4
700 1 _ |a Doecke, James D
|0 0000-0003-2863-0293
|b 5
700 1 _ |a Bellomo, Giovanni
|0 0000-0003-0456-5650
|b 6
700 1 _ |a Vermunt, Lisa
|0 0000-0001-7420-6384
|b 7
700 1 _ |a Alcolea, Daniel
|0 0000-0002-3819-3245
|b 8
700 1 _ |a Halbgebauer, Steffen
|0 P:(DE-2719)9002026
|b 9
700 1 _ |a In 't Veld, Sjors
|b 10
700 1 _ |a Mattsson-Carlgren, Niklas
|b 11
700 1 _ |a Veverova, Katerina
|0 0000-0002-5845-1854
|b 12
700 1 _ |a Fowler, Christopher J
|b 13
700 1 _ |a Boonkamp, Lynn
|b 14
700 1 _ |a Koel-Simmelink, Marleen
|b 15
700 1 _ |a Hussainali, Zulaiga
|b 16
700 1 _ |a Ruiters, Daimy N
|b 17
700 1 _ |a Gaetani, Lorenzo
|0 0000-0003-3967-8954
|b 18
700 1 _ |a Toja, Andrea
|0 0009-0000-9500-7632
|b 19
700 1 _ |a Fortea, Juan
|0 0000-0002-1340-638X
|b 20
700 1 _ |a Pijnenburg, Yolande
|b 21
700 1 _ |a Lemstra, Afina W
|b 22
700 1 _ |a van der Flier, Wiesje M
|0 0000-0001-8766-6224
|b 23
700 1 _ |a Hort, Jakub
|b 24
700 1 _ |a Otto, Markus
|0 0000-0003-4273-4267
|b 25
700 1 _ |a Hansson, Oskar
|0 0000-0001-8467-7286
|b 26
700 1 _ |a Parnetti, Lucilla
|0 0000-0001-5722-3967
|b 27
700 1 _ |a Masters, Colin L
|b 28
700 1 _ |a Lleó, Alberto
|0 0000-0002-2568-5478
|b 29
700 1 _ |a Teunissen, Charlotte E
|0 0000-0002-4061-0837
|b 30
700 1 _ |a Del Campo Milán, Marta
|0 0000-0003-2808-3699
|b 31
773 _ _ |a 10.1038/s41467-025-56293-z
|g Vol. 16, no. 1, p. 1139
|0 PERI:(DE-600)2553671-0
|n 1
|p 1139
|t Nature Communications
|v 16
|y 2025
|x 2041-1723
856 4 _ |u https://pub.dzne.de/record/276323/files/DZNE-2025-00286%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276323/files/DZNE-2025-00286.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276323/files/DZNE-2025-00286.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276323
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9002026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2025-01-02
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NAT COMMUN : 2022
|d 2025-01-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2022
|d 2025-01-02
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-30T07:48:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-30T07:48:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2024-01-30T07:48:07Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21